Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

234.44 +0.57 (+0.25%)
Streaming Delayed Price Updated: 11:01 AM EDT, Sep 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corp

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Should you consider NASDAQ:PODD for growth investing?
Why INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock. 
Via Chartmill
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Why the growth investor may take a look at NASDAQ:PODD.
INSULET CORP (NASDAQ:PODD) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
Expert Ratings for Insulet
Via Benzinga
Why Shares of Insulet Dropped This Week
Positive news regarding diabetes therapy Ozempic worried investors. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Wall Street sees these 2023 losers as 2024 opportunities
Analysts are pointing at undervalued, oversold companies like these three S&P 500 laggards as potential investment opportunities heading into 2024. 
Via MarketBeat
Topics Stocks
Exposures US Equities
What Stocks Drove The Recent Record Rally? A Breakdown You Can't Miss
The technology sector has done well during the recent stock market rally as seen in indices such as Nasdaq 100 and S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
14 Analysts Have This to Say About Insulet
Via Benzinga
Large cap earnings trade ideas for risk-seeking investors
Positive earnings surprises (and the magnitude of surprises) are above historical norms as of late - and these three stocks could keep the party going. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Insulet Surges After Eye-Popping Earnings Growth Wallops Expectations
Insulet makes an insulin pump called Omnipod. U.S. sales are on the rise. 
Via Investor's Business Daily
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Omnipod Insulin Pump Working Well For Insulet, Lifts Annual Forecast
Insulet Corporation (NASDAQ: PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the  
Via Benzinga
Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Spotlights Diabetes Awareness on World Diabetes Day and Throughout November
From Insulet Corporation
Via Business Wire
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone
From Insulet Corporation
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Insulet Stock Traded Lower
Insulet Corporation (NASDAQ: PODD) shares traded lower Thursday. 
Via Benzinga
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
Benzinga 
Via Benzinga
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?
More than 70% of S&P 500 stocks finished in the red last quarter, but the broad-based selloff may be an opportunity - including for these three biggest losers. 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
Exposures Artificial Intelligence Interest Rates US Equities
Tubeless Insulin Pump Technology Provider Insulet's CFO Resigns; Reaffirms Q3, FY23 Outlook
Medical device company Insulet Corp (NASDAQ: PODD) disclosed that Wayde McMillan has decided to resign as Executive Vice President,  
Via Benzinga
Insulet Announces CFO Transition
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
Via Benzinga
FedEx To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Monday
JP Morgan raised the price target for The Progressive Corporation (NYSE: PGR) from $146 to $149. JP Morgan analyst Jimmy Bhullar maintained an Overweight rating. Progressive shares fell 0.8% to close... 
Via Benzinga
Insulet to Present Extended Real-World Evidence and Best Practices for Optimizing Care with Omnipod® 5
From Insulet Corporation
Via Business Wire
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
The broad-market index is up but these stocks are down. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.